Great news! Expanding options in immunotherapy

April 18, 2017
by Stephanie Chisolm

The FDA Granted Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer.

“It is encouraging to see continued progress in the treatment of advanced bladder cancer, which until last year had not seen any major advancements in more than 30 years,” said Andrea Maddox Smith, chief executive officer, Bladder Cancer Advocacy Network. “We are excited that TECENTRIQ is now a treatment option for people with advanced bladder cancer who are unable to receive a cisplatin-based chemotherapy as an initial treatment.”

Read more.

Share this page:Share on FacebookTweet about this on TwitterShare on Google+Share on TumblrShare on LinkedInEmail this to someone